SmurfVA's Random Picks

[Ned Serious]

CYTR- Initiates Pivotal Global Phase 3 Clinical Trial with Aldoxorubicin for Second-Line Treatment of Soft Tissue Sarcoma

I'll still be watching CYTR for an entry in the near future. This is the first positive news since their Dream Team debacle, so will be interesting to see if this helps it consolidate, sells on the news, or helps to start the turnaround up.

link: http://finance.yahoo.com/news/cytrx-initiates-pivotal-global-phase-110000238.html?soc_src=mediacontentstory

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS) under a Special Protocol Assessment with the FDA. Aldoxorubicin combines the chemotherapeutic agent doxorubicin with a novel linker-molecule that binds specifically to albumin in the blood to allow for delivery of higher amounts of doxorubicin (3.5 to 4 times) without several of the major treatment-limiting toxicities seen with administration of doxorubicin alone.